PSNL Personalis, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1527753 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.9%
TTM net income YoY-61.5%
TTM EPS YoY-39.8%
Revenue 3-yr CAGR4.6%
Net income 3-yr CAGR—
Margins
Gross margin16.7%
Operating margin-156.7%
Net margin-147.7%
FCF margin-133.3%
EBITDA margin-144.6%
Returns
ROE-62.1%
ROA-44.7%
ROIC (approx.)-84.8%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets27.1%
Debt / equity0.00x
Current ratio4.53x
Interest coverage-683.98x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue12.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $69.65M | $84.61M |
| Cost of revenue | $53.87M | $57.79M |
| Gross profit | $15.78M | $26.82M |
| R&D expense | $50.26M | $48.91M |
| SG&A expense | $53.57M | $46.19M |
| Operating income | -$88.06M | -$68.27M |
| Interest expense | $205,000 | $24,000 |
| Pretax income | -$81.25M | -$81.27M |
| Income tax | $21,000 | $18,000 |
| Net income | -$81.27M | -$81.28M |
| EBITDA | -$78.01M | -$57.33M |
| EPS (basic) | -0.91 | -1.37 |
| EPS (diluted) | -0.91 | -1.37 |
| Weighted avg. shares (diluted) | 89.24M | 59.25M |
| Balance sheet | ||
| Cash & equivalents | $124.25M | $91.42M |
| Short-term investments | $115.71M | $93.59M |
| Receivables | $16.20M | $8.14M |
| Current assets | $267.95M | $203.01M |
| PP&E, net | $44.81M | $48.27M |
| Total assets | $334.16M | $270.27M |
| Current liabilities | $39.63M | $31.13M |
| Total liabilities | $72.98M | $67.31M |
| Shareholders' equity | $261.19M | $202.96M |
| Shares outstanding | 102.48M | 85.17M |
| Cash flow statement | ||
| Operating cash flow | -$74.95M | -$45.15M |
| Capital expenditure | $4.50M | $1.60M |
| Free cash flow | -$79.45M | -$46.75M |
| Investing cash flow | -$22.57M | -$35.07M |
| Financing cash flow | $130.34M | $114.67M |
| Depreciation & amortization | $10.05M | $10.94M |
| Stock-based compensation | $9.43M | $10.69M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.